iBio acquires multiple assets of AI drug discovery partner RubrYc
September 27, 2022
iBio is jockeying for position as a leading player in AI-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple assets from its partner, RubrYc Therapeutics.